Telomerase inhibition as cancer therapy

Cancer Letters

Volumn 194, Issue 2, 2003, Pages 209-219

  Saretzki, Gabriele ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antisense; Apoptosis; Cancer; Chemotherapeutic drug; G Quartet; hTER; hTERT; Ribozyme; Senescence; Telomerase; Telomerase inhibition; Telomere; Telomere capping; Therapy; Treatment; Tumor

Indexed keywords

2',5' OLIGOADENYLIC ACID; 3 AZIDO 2',3' DIDEOXYTHYMIDINE; 7 DEAZA 2' DEOXYPURINE NUCLEOSIDE TRIPHOSPHATE; ACRIDINE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BERBERINE DERIVATIVE; BIBR 1532; CATECHIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FJ 5002; GELDANAMYCIN; MUTANT PROTEIN; NATURAL PRODUCT; NUCLEOSIDE ANALOG; PACLITAXEL; PORPHYRIN DERIVATIVE; PROTEIN PINX1; RIBOZYME; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE INHIBITOR; TELOMESTATIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISCUM ALBUM EXTRACT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CAPPING PHENOMENON; CELL IMMORTALIZATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE TARGETING; HUMAN; MEDICINAL PLANT; METHODOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; SENESCENCE; TEA; VIRAL GENE THERAPY; VISCUM ALBUM;

EID: 0038701811     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00708-5     Document Type: Article

References (103)

1. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33:1997;787-791.
2. Keith W.N., Bilsland A., Evans T.R.J., Glasspool R.M. Telomerase-directed molecular therapeutics. Expert Rev. Mol. Med. 2002 April 22.
3. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 21:2002;674-679.
4. Chang J.T., Chen Y.L., Yang H.T., Chen C.Y., Cheng A.J. Differential regulation of telomerase activity by six telomerase subunits. Eur. J. Biochem. 269:2002;3442-3450.
5. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilon A.A., Chu C.P., Adams R.R., Chang E., Allsop R.C., Y. Siyuhan Le J., West M.D., Harley C.B., Andrews W.H., Greider C.W., Villeponteau B. The RNA component of human telomerase. Science. 269:1995;1236-1241.
6. Kondo S., Kondo Y., Li G., Silverman R.H., Cowell J.K. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene. 16:1998;3323-3330.
7. Glukhov A.I., Zimnik O.V., Gordeev S.A., Severin S.E. Inhibition of telomerase activity of melanoma cells in vitro by antisense oligonucleotides. Biochem. Biophys. Res. Commun. 248:1998;368-371.
8. Norton J.C., Piatyszek M.A., Wright W.E., Shay J.W., Corey D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat. Biotechnol. 14:1996;615-619.
9. Kanazawa Y., Ohkawa K., Ueda K., Mita E., Takehara T., Sasaki Y., Kasahara A., Hayashi N. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225:1996;570-576.
10. Muller A., Saretzki G., von Zglinicki T. Telomerase inhibition by induced expression of antisense RNA. Adv. Exp. Med. Biol. 451:1998;23-26.
11. Herbert B., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W., Corey D.R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA. 96:1999;14276-14281.
12. Kondo Y., Kondo S., Tanaka Y., Haqqi T., Barna B.P., Cowell J.K. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene. 16:1998;2243-2248.
13. Kondo Y., Koga S., Komata T., Kondo S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component. Oncogene. 19:2000;2205-2211.
14. Koga S., Kondo Y., Komata T., Kondo S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. 8:2001;654-658.
15. Yatabe N., Kyo S., Kondo S., Kanaya T., Wang Z., Maida Y., Takakura M., Nakamura M., Tanaka M., Inoue M. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther. 9:2002;624-630.
16. Kushner D.M., Paranjape J.M., Bandyopadhyay B., Cramer H., Leaman D.W., Kennedy A.W., Silverman R.H., Cowell J.K. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol. 76:2000;183-192.
17. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
18. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Linger J., Harley C.B., Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science. 277:1997;955-959.
19. Zhang X., Mar V., Zhou W., Harrington L., Robinson M.O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13:1999;2388-2399.
20. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., Beijersbergen R.L., Knoll J.H., Meyerson M., Weinberg R.A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5:1999;1164-1170.
21. Yokoyama Y., Takahashi Y., Shinohara A., Lian Z., Wan X., Niwa K., Tamaya T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. 58:1998;5406-5410.
22. Folini M., Colella G., Villa R., Lualdi S., Daidone M.G., Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J. Invest. Dermatol. 114:2000;259-267.
23. Yokoyama Y., Takahashi Y., Shinohara A., Wan X., Takahashi S., Niwa K., Tamaya T. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun. 273:2000;316-321.
24. Qu Y., Liu S.Q., Peng W.Z., Liu B.L. Inhibition of telomerase activity by ribozyme targeted to human telomerase transcriptase [in Chinese]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 34:2002;323-328.
25. Ludwig A., Saretzki G., Holm P.S., Tiemann F., Lorenz M., Emrich T., Harley C.B., von Zglinicki T. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 61:2001;3053-3061.
26. Lorenz M., Saretzki G., Sitte N., Metzkow S., von Zglinicki T. BJ fibroblasts display high antioxidant capacity and slow telomere shortening independent of hTERT transfection. Free Radic. Biol. Med. 31:2001;824-831.
27. Saretzki G., Ludwig A., von Zglinicki T., Runnebaum I.B. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther. 8:2001;827-834.
28. Griffith J.D., Comeau L., Rosenfield S., Stansel R.M., Bianchi A., Moss H., de Lange T. Mammalian telomeres end in a large duplex loop. Cell. 97:1999;503-514.
29. Makarov V.L., Hirose Y., Langmore J.P. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 88:1997;657-666.
30. Sen D., Gilbert W. Formation of parallel four-stranded complexes by guanine-rich motifs in DNA and its implications for meiosis. Nature. 334:1988;364-366.
31. Liu Z., Lee A., Gilbert W. Gene disruption of a G4-DNA-dependent nuclease in yeast leads to cellular senescence and telomere shortening. Proc. Natl. Acad. Sci. USA. 92:1995;6002-6006.
32. Rezler E.M., Bearss D.J., Hurley L.H. Telomeres and telomerases as drug targets. Curr. Opin. Pharmacol. 2:2002;415-423.
33. Gowan S.M., Heald R., Stevens M.F., Kelland L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol. Pharmacol. 60:2001;981-988.
34. Gowan S.M., Harrison J.R., Patterson L., Valenti M., Read M.A., Neidle S., Kelland L.R. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol. 61:2002;1154-1162.
35. Blackburn E. The telomere and telomerase: how do they interact? Mt. Sinai J. Med. 66:1999;292-300.
36. Blackburn E.H. Telomere states and cell fates. Nature. 408:2000;53-56.
37. Blackburn E.H. Switching and signaling at the telomere. Cell. 106:2001;661-673.
38. de Lange T. Protection of mammalian telomeres. Oncogene. 21:2002;532-540.
39. Kim M.M., Rivera M.A., Botchkina I.L., Shalaby R., Thor A.D., Blackburn E.H. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc. Natl. Acad. Sci. USA. 98:2001;7982-7987.
40. Cao Y., Li H., Deb S., Liu J.P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene. 21:2002;3130-3138.
41. Blasco M.A. Opinion: Telomerase beyond telomeres. Nat. Rev. Cancer. 2:2002;627-633.
42. Stansel R.M., de Lange T., Griffith J.D. T-loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang. EMBO J. 20:2001;5532-5540.
43. Zhou X.Z., Lu K.P. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 107:2001;347-359.
44. Ishibashi K., Wakasugi S., Ogawa K., Kato H., Endo S., Yoshimatsu K., Haga S., Hirose K., Kajiwara T. Detection of telomerase activity in intestinal lavage solution from colorectal carcinoma patients [in Japanese]. Nippon Rinsho. 56:1998;1209-1213.
45. Zhang R.G., Zhang R.P., Wang X.W., Xie H. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells. Cell Res. 12:2002;55-62.
46. Kondo Y., Komata T., Kondo S. Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int. J. Oncol. 18:2001;1287-1292.
47. Folini M., De Marco C., Orlandi L., Daidone M.G., Zaffaroni N. Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur. J. Cancer. 36:2000;2137-2145.
48. Lee K.H., Rudolph K.L., Ju Y.J., Greenberg R.A., Cannizzaro L., Chin L., Weiler S.R., DePinho R.A. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc. Natl. Acad. Sci. USA. 98:2001;3381-3386.
49. Yoon H.J., Choi I.Y., Kang M.R., Kim S.S., Muller M.T., Spitzner J.R., Chung I.K. DNA topoisomerase II cleavage of telomeres in vitro and in vivo. Biochim. Biophys. Acta. 1395:1998;110-120.
50. Elmore L.W., Rehder C.W., Di X., McChesney P.A., Jackson-Cook C.K., Gerwirtz D.A., Holt S.E. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 2002;35509-35515.
51. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 27:2002;339-344.
52. Cressey T.R., Tilby M.J., Newell D.R. Decreased telomerase activity is not a reliable indicator of chemosensitivity in testicular cancer cell lines. Eur. J. Cancer. 38:2002;586-593.
53. Lyu S.Y., Choi S.H., Park W.B. Korean mistletoe lectin-induced apoptosis in hepatocarcinoma cells is associated with inhibition of telomerase via mitochondrial controlled pathway independent of p53. Arch. Pharm. Res. 25:2002;93-101.
54. Giridharan P., Somasundaram S.T., Perumal K., Vishwakarma R.A., Karthikeyan N.P., Velmurugan R., Balakrishnan A. Novel substituted methylenedioxy lignan suppresses proliferation of cancer cells by inhibiting telomerase and activation of c-myc and caspases leading to apoptosis. Br. J. Cancer. 87:2002;98-105.
55. Naasani I., Seimiya H., Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem. Biophys. Res. Commun. 249:1998;391-396.
56. Kim M.Y., Vankayalapati H., Shin-Ya K., Wierzba K., Hurley L.H. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am. Chem. Soc. 124:2002;2098-2099.
57. Lian Z., Fujimoto J., Yokoyama Y., Niwa K., Tamaya T. Herbal complex suppresses telomerase activity in chemo-endocrine resistant cancer cell lines. Eur. J. Gynaecol. Oncol. 22:2001;347-349.
58. Strahl C., Blackburn E.H. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 16:1996;53-65.
59. Melana S.M., Holland J.F., Pogo B.G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin Cancer Res. 4:1998;693-696.
60. Tejera A.M., Alonso D.F., Gomez D.E., Olivero O.A. Chronic in vitro exposure to 3′-azido-2′,3′-dideoxythymidine induces senescence and apoptosis and reduces tumorigenicity of metastatic mouse mammary tumor cells. Breast Cancer Res. Treat. 65:2001;93-99.
61. Olivero O.A., Poirier M.C. Preferential incorporation of 3′-azido-2′,3′-dideoxythymidine into telomeric DNA and Z-DNA-containing regions of Chinese hamster ovary cells. Mol. Carcinog. 8:1993;81-88.
62. Fletcher T.M., Cathers B.E., Ravikumar K.S., Mamiya B.M., Kerwin S.M. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate. Bioorg. Chem. 29:2001;36-55.
63. Naasani I., Seimiya H., Yamori T., Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res. 59:1999;4004-4011.
64. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., Niestroj C., Daiber C., Enenkel B., Guilliard B., Lauritsch I., Muller E., Pascolo E., Sauter G., Pantic M., Martens U.M., Wenz C., Lingner J., Kraut N., Rettig W.J., Schnapp A. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20:2001;6958-6968.
65. Pascolo E., Wenz C., Lingner J., Hauel N., Priepke H., Kauffmann I., Garin-Chesa P., Rettig W.J., Damm K., Schnapp A. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J. Biol. Chem. 277:2002;15566-15572.
66. Holt S.E., Aisner D.L., Baur J., Tesmer V.M., Dy M., Ouellette M., Trager J.B., Morin G.B., Toft D.O., Shay J.W., Wright W.E., White M.A. Functional requirement of p23 and Hsp90 in telomerase complexes. Genes Dev. 13:1999;817-826.
67. Cong Y.S., Wen J., Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum. Mol. Genet. 8:1999;137-142.
68. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59:1999;551-557.
69. Poole J.C., Andrews L.G., Tollefsbol T.O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene. 269:2001;1-12.
70. Zhao J.Q., Hoare S.F., McFarlane R., Muir S., Parkinson E.K., Black D.M., Keith W.N. Cloning and characterization of human and mouse telomerase RNA gene promoter sequences. Oncogene. 16:1998;1345-1350.
71. Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., Ariga H., Inoue M. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res. 28:2000;669-677.
72. Wang Z., Kyo S., Takakura M., Tanaka M., Yatabe N., Maida Y., Fujiwara M., Hayakawa J., Ohmichi M., Koike K., Inoue M. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 60:2000;5376-5381.
73. Gunes C., Lichtsteiner S., Vasserot A.P., Englert C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res. 60:2000;2116-2121.
74. Oh S., Song Y.H., Yim J., Kim T.K. Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene. 19:2000;1485-1490.
75. Oh S., Song Y., Yim J., Kim T.K. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J. Biol. Chem. 274:1999;37473-37478.
76. Oh S., Song Y.H., Kim U.J., Yim J., Kim T.K. In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells. Biochem. Biophys. Res. Commun. 263:1999;361-365.
77. Crowe D.L., Nguyen D.C., Tsang K.J., Kyo S. E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res. 29:2001;2789-2794.
78. Grand C.L., Han H., Muñoz R.M., Weimann S., Von Hoff D.D., Hurley L.H., Bearss D.J. The cationic porphyrin TMPyP4 downregulates c-Myc and hTERT expression and inhibits tumor growth in vivo. Mol. Cancer Ther. 1:2002;565-573.
79. Li H., Lee T.H., Avraham H. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277:2002;20965-20973.
80. Colgin L.M., Wilkinson C., Englezou A., Kilian A., Robinson M.O., Reddel R.R. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2:2000;426-432.
81. Cerezo A., Kalthoff H., Schuermann M., Schafer B., Boukamp P. Dual regulation of telomerase activity through c-Myc-dependent inhibition and alternative splicing of hTERT. J. Cell Sci. 115:2002;1305-1312.
82. Kyo S., Takakura M., Kanaya T., Zhuo W., Fujimoto K., Nishio Y., Orimo A., Inoue M. Estrogen activates telomerase. Cancer Res. 59:1999;5917-5921.
83. Misiti S., Nanni S., Fontemaggi G., Cong Y.S., Wen J., Hirte H.W., Piaggio G., Sacchi A., Pontecorvi A., Bacchetti S., Farsetti A. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol. Cell. Biol. 20:2000;3764-3771.
84. Pendino F., Flexor M., Delhommeau F., Buet D., Lanotte M., Segal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc. Natl. Acad. Sci. USA. 98:2001;6662-6667.
85. Ding Z., Green A.G., Yang X., Chernenko G., Tang S.C., Pater A. Retinoic acid inhibits telomerase activity and downregulates expression but does not affect splicing of hTERT: correlation with cell growth rate inhibition in an in vitro cervical carcinogenesis/multidrug-resistance model. Exp. Cell Res. 272:2002;185-191.
86. Cong Y.S., Bacchetti S. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J. Biol. Chem. 275:2000;35665-35668.
87. Aldous W.K., Marean A.J., DeHart M.J., Matej L.A., Moore K.H. Effects of tamoxifen on telomerase activity in breast carcinoma cell lines. Cancer. 85:1999;1523-1529.
88. Wang Z., Kyo S., Maida Y., Takakura M., Tanaka M., Yatabe N., Kanaya T., Nakamura M., Koike K., Hisamoto K., Ohmichi M., Inoue M. Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene. 21:2002;3517-3524.
89. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature. 345:1990;458-460.
90. von Zglinicki T., Saretzki G., Docke W., Lotze C. Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence? Exp. Cell Res. 220:1995;186-193.
91. Petersen S., Saretzki G., von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp. Cell Res. 239:1998;152-160.
92. Plumb J.A., Bilsland A., Kakani R., Zhao J., Glasspool R.M., Knox R.J., Evans T.R., Keith W.N. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene. 20:2001;7797-7803.
93. Gu J., Kagawa S., Takakura M., Kyo S., Inoue M., Roth J.A. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res. 60:2000;5359-5364.
94. Mukai S., Kondo Y., Koga S., Komata T., Barna B.P., Kondo S. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res. 60:2000;4461-4467.
95. Fu W., Begley J.G., Killen M.W., Mattson M.P. Anti-apoptotic role of telomerase in pheochromocytoma cells. J. Biol. Chem. 274:1999;7264-7271.
96. Zhu H., Fu W., Mattson M.P. The catalytic subunit of telomerase protects neurons against amyloid beta-peptide-induced apoptosis. J. Neurochem. 75:2000;117-124.
97. Lu C., Fu W., Mattson M.P. Telomerase protects developing neurons against DNA damage-induced cell death. Brain Res. Dev. Brain Res. 131:2001;167-171.
98. Mattson M.P., Fu W., Zhang P. Emerging roles for telomerase in regulating cell differentiation and survival: a neuroscientist's perspective. Mech. Ageing Dev. 122:2001;659-671.
99. Cao Y., Li H., Mu F.T., Ebisui O., Funder J.W., Liu J.P. Telomerase activation causes vascular smooth muscle cell proliferation in genetic hypertension. FASEB J. 16:2002;96-98.
100. Oh H., Schneider M.D. The emerging role of telomerase in cardiac muscle cell growth and survival. J. Mol. Cell. Cardiol. 34:2002;717-724.
101. Page T.J., Mata J.E., Bridge J.A., Siebler J.C., Neff J.R., Iversen P.L. The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells. Exp. Cell Res. 252:1999;41-49.
102. Saretzki G., Sitte N., Merkel U., Wurm R.E., von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene. 18:1999;5148-5158.
103. Holt S.E., Glinsky V.V., Ivanova A.B., Glinsky G.V. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol. Carcinog. 25:1999;241-248.